Related Experiment Video
Updated: Jun 12, 2026
05:35
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
Cost-Effectiveness of Transrectal and Transperineal Prostate Biopsy: Analysis from the ProBE-PC Randomized Study
Fortis Gaba1, Adrian J Waisman Malaret1, Paul J Feustel2
1Department of Urology, Albany Medical Center, Albany, New York.
Urology Practice
|June 10, 2026
Summary
Transperineal prostate biopsy (TP-Bx) is significantly more expensive than transrectal biopsy (TR-Bx) due to higher supply and personnel costs. Despite similar complication rates, TP-Bx incurs higher overall healthcare costs.
Area of Science:
- Urology
- Health Economics
Background:
- Cost analyses are crucial for evidence-based healthcare decisions.
- Previous studies show minimal differences in cancer detection and complications between transrectal biopsy (TR-Bx) and transperineal biopsy (TP-Bx).
Purpose of the Study:
- To conduct a comprehensive cost analysis of TR-Bx and TP-Bx.
- To evaluate associated healthcare utilization for both prostate biopsy methods.
Main Methods:
- A randomized study involving 718 men comparing TR-Bx and TP-Bx under local anesthesia.
- Modified time-driven activity-based costing was used, including supplies, personnel time, and complication costs.
- Actual institutional costs and payments were utilized for the analysis.
Main Results:
- TP-Bx had a significantly higher procedural cost ($323.78) than TR-Bx ($124.28), driven by disposable instruments and personnel time.
- Complication costs per biopsy were similar between TP-Bx ($11.13) and TR-Bx ($19.26).
- The total median cost, including complications, was significantly higher for TP-Bx ($326.78) versus TR-Bx ($126.29).
Conclusions:
- Transperineal biopsy under local anesthesia is significantly more costly than transrectal biopsy.
- These cost differences are important considerations for selecting biopsy techniques and managing healthcare utilization in clinical practice.
